Logan Capital Management Inc. Sells 12,989 Shares of Lantheus Holdings, Inc. $LNTH

Logan Capital Management Inc. decreased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 49.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,330 shares of the medical equipment provider’s stock after selling 12,989 shares during the quarter. Logan Capital Management Inc.’s holdings in Lantheus were worth $1,091,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Signaturefd LLC lifted its position in shares of Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 116 shares in the last quarter. Quarry LP lifted its position in shares of Lantheus by 2,350.0% during the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 470 shares in the last quarter. Hughes Financial Services LLC bought a new position in shares of Lantheus during the 1st quarter worth approximately $81,000. GAMMA Investing LLC lifted its position in shares of Lantheus by 29.3% during the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock worth $128,000 after buying an additional 298 shares in the last quarter. Finally, AlphaQuest LLC lifted its position in shares of Lantheus by 252.5% during the 1st quarter. AlphaQuest LLC now owns 1,653 shares of the medical equipment provider’s stock worth $161,000 after buying an additional 1,184 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling

In other news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the company’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Rajiv A. Patel sold 3,365,000 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,812,000 shares of company stock valued at $382,427,380 over the last quarter. 2.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several recent analyst reports. JMP Securities dropped their target price on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 7th. Weiss Ratings cut shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday. William Blair reissued a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th. Truist Financial set a $63.00 target price on shares of Lantheus and gave the stock a “hold” rating in a research report on Monday, August 11th. Finally, The Goldman Sachs Group set a $77.00 target price on shares of Lantheus and gave the stock a “neutral” rating in a research report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Hold” and a consensus price target of $74.50.

Lantheus Trading Down 1.4%

Shares of LNTH stock opened at $57.33 on Wednesday. The company has a 50 day moving average of $54.23 and a 200-day moving average of $71.05. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $118.21. The firm has a market cap of $3.90 billion, a P/E ratio of 15.25 and a beta of 0.09.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The company had revenue of $92.51 million during the quarter. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.